Amylases Inhibitor

α-Amylase-IN-5 (compound 3a) is a α-amylase inhibitor, with an IC₅₀ of 18.8 mM.

α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of α-Amylase and α-Glucosidase with IC₅₀s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research.

α-Amylase-IN-8 (compound 44) ​​is an α-amylase inhibitor (IC₅₀=58.1 μM). α-Amylase-IN-8 can be used in the research of type 2 diabetes.

Carveol (Standard) is the analytical standard of Carveol. This product is intended for research and analytical applications. Carveol is an orally active monoterpenoid alcohol with neuroprotective, antioxidant, anti-inflammatory, anticonvulsant, antidiabetic, hypolipidemic and hepatoprotective activities. Carveol upregulates the expression of Bcl2, downregulates the expression of caspase-3, TNF-α, IL1β and IL6, activates the Nrf2/HO-1 antioxidant signaling pathway, inhibits the RAGE/NF-κB signaling pathway, and suppresses neuroinflammation and neuronal apoptosis. Carveol inhibits α-synuclein aggregation, improves cognitive ability, and inhibits α-amylase activity. Carveol exerts neuroprotective effects in a rat model of Parkinson's disease. Carveol exhibits antidiabetic effects in alloxan-induced diabetic rats. Carveol alleviates PTZ-induced seizures in rats. Carveol can be used in research related to Parkinson's disease, epilepsy, diabetes and ischemic stroke.

3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of α-Amylase with the inhibitory activity of 28.3% at 500 μM.

α-Amylase/α-Glucosidase-IN-24 is a dual inhibitor of α-amylase and α-glucosidase, with IC₅₀ values of 40.18 μg/mL and 31.80 μg/mL, respectively. α-Amylase/α-Glucosidase-IN-24 exhibits weak anti-inflammatory and antioxidant activities, as well as moderate antibacterial activity. α-Amylase/α-Glucosidase-IN-24 can be used for the research of type 2 diabetes.

Stigmast-5-en-3-ol induces cancer cell apoptosis and inhibits proliferation by increasing the production of Bax, Caspase-9, p53, and PARP cleavage and reducing Bcl-xl expression. Stigmast-5-en-3-ol exhibits potent inhibitory activity against glucoamylase and α-amylase and possesses high antioxidant activity. Stigmast-5-en-3-ol can be used in the research of diseases such as leukemia, breast cancer, type 2 diabetes, and obesity.

MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC₅₀: 26.8 nM), with weak activity against hMAO-A (IC₅₀: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC₅₀: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC₅₀ values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance.

E234G HYPE-IN-1 (Compound I2.10) is an inhibitor of AMPylation directed by the Huntingtin-interacting protein E (HYPE), possessing low micromolar bioactivity, low cytotoxicity, and blood-brain barrier permeability. E234G HYPE-IN-1 can inhibit the AMPylation of B-cell immunoglobulin-binding protein (BiP), the primary substrate of HYPE. E234G HYPE-IN-1 is suitable for development as a HYPE-specific therapeutic agent for clinical conditions such as neurodegenerative diseases and diabetes.

α-Glucosidase-IN-105 is a selective and potent α-Glucosidase inhibitor with an IC₅₀ of 31.36 μM. α-Glucosidase-IN-105 also inhibits α-Amylase (IC₅₀ = 104.2 μM). α-Glucosidase-IN-105 exhibits inhibitory effects comparable to the standard drug \rAcarbose (HY-B0089). α-Glucosidase-IN-105 can be used for the research of type 2 diabetes.

DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC₅₀=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC₅₀=3.02 μM) and α-amylase (IC₅₀=3.3 μM).

α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of α-Glucosidase and α-amylase, with the IC₅₀s of 21 μM and 61 μM, respectively.

Decussatin is an α-Amylases inhibitor isolated from the Tibetan medicinal plant Swertia mussotii. By inhibiting the catalytic activity of α-Amylases, Decussatin reduces the hydrolysis of complex carbohydrates such as starch and the intestinal absorption of glucose, thereby lowering blood glucose levels in the body. Decussatin shows no significant in vitro antibacterial or antifungal activity. Decussatin can be used for the research of type 2 diabetes.

α-Amylase-IN-9 (Compound 1i) is an inhibitor of α-Amylase with an IC₅₀ value of 14.64 μM, which can be used in diabetes research.

α-Amylase-IN-14, a derivative of Nicotinic (HY-B0143), is an α-amylase inhibitor and has good interactions with α-amylase protein (-5.55 kcal/mol). α-Amylase-IN-14 is a dual anti-inflammatory and anti-hyperglycemic agent. α-Amylase-IN-14 exhibits good results against DPPH and ABTS radicals. α-Amylase-IN-14 can be used for the study of diabetes.

4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC₅₀ values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM.

α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of α-Amylase/α-Glucosidase that can be used for diabetes research.

α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits α-amylase (IC₅₀ = 30.39 μM) and α-glucosidase (IC₅₀ = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier.

α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity.

HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively.